GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Bank of New York Mellon Corp lowered its position in GSK PLC Sponsored ADR (NYSE: GSK) by 13.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 808,139 shares of the pharmaceutical company's stock after selling 129,449 shares during the period. Bank of New York
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.
GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.
Bank of New York Mellon Corp lowered its position in GSK PLC Sponsored ADR (NYSE: GSK) by 13.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 808,139 shares of the pharmaceutical company's stock after selling 129,449 shares during the period. Bank of New York
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.
GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.
Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC GSK's first approval in lung cancer, part of a growing portfolio of targeted treatments LONDON, July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.1 The approval comes ahead of the original target action date of 18 September 2026 and follows the FDA's Breakthrough Therapy and Orphan Drug Designations.2 Jideytro, part of the portfolio from the recently completed acquisition of Nuvalent, Inc. 3, was developed to address key efficacy and/or tolerability challenges of treating ROS1-postive NSCLC. Its next-generation design aims to combine high target-selectivity, broad coverage of ROS1 resistance mutations and blood-brain barrier penetration to address disease in the brain.
GSK said on Wednesday the U.S. FDA has approved its drug for adults with a form of lung cancer who have previously received a targeted therapy.
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK (GSK) trades at a 42% discount to pharma peers, despite resilient earnings projections through the dolutegravir patent cliff. The HIV franchise's shift to long-acting injectables, protected by new IP, is driving 30–44% growth and mitigating generic risk. Nuvalent acquisition brings two near-term oncology launches, expected to improve margins and offset dolutegravir LOE impact.
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.
GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb study for irritable bowel syndrome.
GSK plc (NYSE:GSK) on Friday announced a pivotal update regarding its Phase 3 clinical program for camlipixant, revealing a strategic decision to halt further development for refractory chronic cough (RCC).
Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price target, implying roughly 30% upside from the 1,916.50p close. The broker argues a run of business development deals has brought the drugmaker's £40 billion 2031 revenue target within reach without straining the profit and loss account.
GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.
GSK on Friday said it had decided not to develop its experimental drug to treat refractory chronic cough further after it did not meet one of its main goals in a late-stage trial.
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from...
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from new chief executive Luke Miels. The bank reiterated its 'neutra'l rating on GSK ahead of results and a capital markets day due on 28 July.
GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more after treatment for a specific type of locally advanced rectal cancer.
British drugmaker GSK's experimental drug for treating patients with advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial on Friday.
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to market two respiratory drugs from British company GSK in mainland China.
GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and Jemperli, I believe Exdensur could become another meaningful growth driver.
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, via partnership with GSK. SPRO stands to receive milestone payments and royalties from GSK, with potential annual earnings of ~$50m and upside if Utebzi achieves blockbuster status. Despite a volatile share price and limited pipeline, SPRO's low burn rate and funding runway into 2028 support a 'buy the dip' thesis for risk-tolerant investors.
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This app.
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis1, caused by certain susceptible pathogens2 in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This approval is a result of GSK's development and exclusive global licensing agreement (excluding select Asian territories) with Spero Therapeutics.iv
The U.S. FDA has approved GSK's oral antibiotic to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option against drug-resistant infections.
Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.
GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase II/III study.
On June 11, 2026, GSK PLC (GSK) shares rose 3.3% to a current price of $52.86. The stock has shown strong momentum over the past year, with a 31.8% increase, an
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZeneca and Roche.
GSK plc (GSK) M&A Call Transcript
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
GSK PLC's (LSE:GSK, NYSE:GSK) $10.6 billion (£8bn) acquisition of US biotech Nuvalent has achieved something unusual in large pharmaceutical M&A: analysts broadly agree it makes sense. The debate is less about whether the deal is strategically sound and more about how much upside remains after shelling out a chunky amount for two relatively mature assets.
Thistle Resources (TSX-V:TRCG, OTC:TRCGF) has intersected broad, high-grade gold mineralization at its Middle River Gold Project, the company said...
Snail Inc (NASDAQ:SNAL) has launched its open-world kingdom-building survival RPG Bellwright on PlayStation and Xbox, extending a title that has surpassed...
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value...
Abacus Global Management (NYSE:ABX) has unveiled LifeARC, a proprietary AI-powered platform that generates personalized lifespan models for individuals...
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
GSK (GSK) is experiencing a modest uptick in its stock price following the announcement of its acquisition of Nuvalent (NUVL) for $124 per share, totaling $10.6
Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) price target to $140 from $115, and GSK's (GSK) new $10.6 billon acquisition of Nuvalent (NUVL).
Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, very good deal;" OpenAI has confidentially filed with the SEC for an IPO, but said in a statement it doesn't have a timeline for going public; Nuvalent shares are soaring after the drugmaker agreed to be acquired by British pharmaceutical giant GSK; and Vail Resorts shares are down after the company cut its outlook for the second time this year. Here's what you need to know today.
Nuvalent shares catapulted to a record high Tuesday after GSK made an all-cash bid to buy the small biotech company for $10.6 billion.
Nuvalent Inc (NASDAQ:NUVL) is soaring in premarket trading, up 38.9% to trade at $122.88, after London-based GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion.
GSK (GSK) has agreed to acquire Nuvalent Inc. (NUVL) in a $10.6 billion cash deal, giving the British pharmaceutical company a bigger foothold in precision onco
Multiple notable acquisitions hit the market, OpenAI submits IPO documents, and more
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and offset looming patent expirations in its HIV portfolio. The acquisition, announced on Tuesday, will give the British pharmaceutical giant access to three experimental lung cancer treatments, including two candidates currently under review by the US Food and Drug Administration and expected to receive regulatory decisions later this year.
GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where the stock traded as of Monday's close.
GSK PLC (LSE:GSK, NYSE:GSK) shares fell 3% after it agreed to acquire US biotechnology company Nuvalent (NASDAQ:NUVL) for $10.6 billion (£8.0 billion),...
The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal valued at $10.6 billion. By 0810 GMT, the blue-chip FTSE 100 had slipped 0.3% to 10,341 points.
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire US biotechnology company Nuvalent for $10.6 billion (£8.0 billion), adding "immediate" new sales growth opportunities, as well as a trio of advanced lung cancer drugs and other assets to boost its oncology pipeline. The FTSE 100 pharmaceuticals group said the deal would contribute to revenue growth from 2027 and be accretive to core operating profit in 2027 and core earnings per share in 2029, including synergies and reprioritisation.
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.
British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion.
UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report. The companies have been in discussions with the aim of finalizing a deal as early as this week.
UK pharmaceutical group GSK is in talks to buy cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported on Monday, citing people familiar with the matter.
Collaboration leverages Engitix's human ECM Platform to identify high-confidence targets for liver fibrosis regression Collaboration leverages Engitix's human ECM Platform to identify high-confidence targets for liver fibrosis regression
Longspur Research has initiated coverage of Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S), the battery materials company, with a central case valuation of 153p...
The UK's benchmark FTSE 100 index fell to its lowest level in more than two weeks on Thursday, weighed down by sharp declines in Asia-focused lenders and miners after reports of tighter offshore banking restrictions in China. Lower crude oil prices also dragged energy stocks lower, adding to the market's weakness.
Jefferies has flagged four near-term catalysts in GSK PLC's (LSE:GSK, NYSE:GSK) oncology pipeline following a fireside chat with the pharmaceutical...
Jefferies has flagged four near-term catalysts in GSK PLC's (LSE:GSK, NYSE:GSK) oncology pipeline following a fireside chat with the pharmaceutical company's global head of oncology and research and development at the bank's New York healthcare conference, reiterating its buy rating and 2,500p price target on the stock. GSK, which is trading at 1,872p, plans to present additional datasets for its B7H3 antibody-drug conjugate.
Gunnison Copper Corp (TSX:GCU, OTCQB:GCUMF, FRA:3XS0) has announced plans for a district-wide drilling program at its Gunnison copper project, including the...
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.
UBS has described the UK equity market as an "incomplete plate rather than an empty one" in its latest monthly strategy note, concluding that disciplined stock selection rather than broad index exposure is the right approach. The bank's REVS framework, which assesses regime, earnings, valuation and sentiment across a two to six month tactical horizon, assigns the UK market a fragile score, one notch below constructive, with earnings now the strongest supportive pillar and sentiment the most significant drag.
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that...
Citi is holding back from recommending GSK PLC (LSE:GSK, NYSE:GSK) shares despite a significant clinical breakthrough in hepatitis B treatment, arguing that unanswered commercial questions mean any value from the new drug is unlikely to materialise for shareholders in the near term. The bank maintains its 'neutral' rating on GSK after trial results for the company's experimental drug bepirovirsen were published in the New England Journal of Medicine.
Sonoro Gold Corp (TSX-V:SGO, OTCQB:SMOFF, FRA:23SP) said on Friday that it has increased the size of its previously announced non-brokered private placement...
GSK (GSK) may have just strengthened the investment case around one of its most important pipeline assets. Late-stage data showed bepirovirsen, its experimental
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
Drug candidate bepirovirsen helped nearly a fifth of patients in two late-stage clinical trials achieve a functional cure, the company said.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress. GSK licensed bepirovirsen from Ionis an.
GSK said its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, raising hopes for a finite treatment course as an alternative to lifelong antiviral pills.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
A clutch of heavyweight dividend payments knocked almost 20 points off the FTSE 100 on Thursday, with four of the index's biggest companies trading ex-dividend. HSBC Holdings PLC (LSE:HSBA) had the largest impact, removing 5.36 points from the blue-chip index as the shares traded without entitlement to the bank's latest 10-cent quarterly payout.
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mainland China.
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight...
Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight rating on GSK PLC (LSE:GSK, NYSE:GSK) with a June 2027 price target of £17, arguing that near-term earnings upgrade potential is limited and that the pharmaceutical group's longer-term outlook remains contingent on pipeline success and the execution of new product launches. Analyst Zain Ebrahim made modest forecast changes following GSK's first-quarter 2026 results, including foreign exchange-related adjustments of 0% to 1% to sales forecasts across 2026 to 2031 and upgrades of 1% to 2% to core operating profit estimates.
Ideal Power Inc (NASDAQ:IPWR, FRA:5ILA), developer of its B-TRAN bidirectional semiconductor power switch, said management will host a conference call on...
OTC Markets Group Inc. (OTCQX:OTCM) announced that Charlotte’s Web Holdings, a botanical wellness innovation company, has qualified to trade on the OTCQX...
GSK plc (GSK) Q1 2026 Earnings Call Transcript
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.13 per share a year ago.
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giants have recently said that Europe risks losing out on new medicines as drug prices in the U.S. market are tied to lower prices elsewhere under Trump's MFN policy.
GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 guidance after delivering a strong first quarter, with core operating profit growth and earnings per share both expected to rise between 7% and 9% at constant exchange rates. Turnover growth is forecast to be between 3% and 5%, supported by expectations of low double-digit growth in Specialty Medicines, offset by low single-digit declines to stable performance in both Vaccines and General Medicines.
